Hypervision Surgical raises £6.5m in seed funding led by HERAN Partners and others to advance surgical imaging technology
The seed round was backed by HERAN Partners, Redalpine, LifeX Ventures, and ZEISS Ventures.
Hypervision Surgical is a King's College London spin-out developing an advanced surgical imaging and data analytics platform. The firm utilises artificial intelligence and clinical edge computing to improve intraoperative decision-making.
London-based medical technology firm Hypervision Surgical has secured £6.5m in a seed funding round. The investment was led by a syndicate of European and American health technology backers, including HERAN Partners, Redalpine, LifeX Ventures, and ZEISS Ventures.
The capital will be directed towards accelerating the development of the company's optical vision technology and achieving regulatory clearance in the United States and Europe. Furthermore, the funds will support clinical evaluations and expand strategic partnerships with medical centres.
The King's College London spin-out combines hyperspectral imaging with edge computing to assist surgeons in distinguishing between healthy and diseased tissue during complex procedures.
From the founder
"We are incredibly excited about the transformative potential of our Hyperspectral Intelligence platform"
Michael Ebner
CEO and co-founder at Hypervision Surgical
Investor perspective
"Hypervision Surgical’s hardware- agnostic solution has the potential to redefine the standard of care in surgical imaging across various procedures, from open to minimally invasive, robotics, and microscopic surgeries."
Raf Roelands
Investment Director, HERAN Partners
Use of funds
- 01Continue product development
- 02Expand into international markets
Investors
Categories
About the company
Hypervision Surgical
Hypervision Surgical develops an advanced surgical imaging and data analytics platform.